Based on a just-completed study involving 131 patients, Israel’s Neuronix medical device company will apply for U.S. FDA approval for its neuroAD system to slow and even reverse the progression of Alzheimer’s, Israel21c reports.
The novel technology combines transcranial magnetic stimulation (TMS) and cognitive training of specific brain regions to slow the rate of mental deterioration in patients with mild to moderate Alzheimer’s and other neurodegenerative disorders. The treatment is commercially available in Europe and Asia, including in Israel.
Neuronix CEO Eyal Baror said, “Our previous successful six clinical trials have shown that neuroAD is safe and effective in treatment of mild to moderate Alzheimer patients, significantly improving their cognitive performance and day-to-day activities, and slowing down their mental deterioration for about one year.”
In 2015, Korean researchers said a clinical trial showed that neuroAD “was remarkable in the memory and language domains, which are severely affected by Alzheimer’s disease.”
David Steger – Matzav.com Israel